{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:03:47Z","timestamp":1785236627927,"version":"3.55.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Currently, treatment options for patients with advanced melanoma who experience failed immunotherapy or targeted therapy are lacking. Recent studies suggest the antitumor activity of combined pembrolizumab and lenvatinib in patients with advanced melanoma progressing on immunotherapy. Herein, we report the clinical outcomes of combined lenvatinib and a programmed cell death protein-1 inhibitor (PD-1) in this population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>This French multicenter real-world study was conducted between September 2020 and July 2023. The primary endpoint was the objective response rate (ORR) according to the Response Evaluation Criteria in Solid Tumours (version 1.1). Secondary variables were treatment-related adverse events (TRAEs), progression-free survival (PFS), overall survival (OS), and duration of response (DOR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 67 patients included (median age, 69 years; median follow-up, 5.0 months), 85% had stage IV-M1c or M1d disease. The overall ORR was 28.4% (95% CI, 18%-41%), including 3 complete (4.5%) and 16 partial (23.9%) responses. Median DOR was 3.1 (interquartile range, 1.3-4.3) months. Median PFS and OS were 3.1 (95% CI, 2.5-3.7) and 9.8 (95% CI, 5.6-13.9) months, respectively. Grades 3-5 TRAEs occurred in 16 (24%) patients; common TRAEs were fatigue (43.3%), nausea\/vomiting (26.8%), diarrhea (20.9%), and hypertension (20.9%). No treatment-related deaths occurred.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our real-world study demonstrates an interesting response rate and acceptable safety profile in a population with poor prognostic factors. Our data support this treatment option for refractory melanoma, as it is not approved by the Food and Drug Administration or European Medicines Agency, and highlight the need for new strategies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae145","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T04:05:25Z","timestamp":1719979525000},"page":"e1364-e1372","source":"Crossref","is-referenced-by-count":6,"title":["Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: the Lenvamel study, a multicenter retrospective study of the French Group of Skin Cancers (Groupe de Canc\u00e9rologie Cutan\u00e9e)"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4666-5641","authenticated-orcid":false,"given":"Perrine","family":"Rousset","sequence":"first","affiliation":[{"name":"University Hospital of Nice Dermatology Department, , Nice ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charl\u00e9e","family":"Nardin","sequence":"additional","affiliation":[{"name":"University Hospital of Besan\u00e7on, Universit\u00e9 de Franche-Comt\u00e9 Dermatology Department, , Besan\u00e7on ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Maubec","sequence":"additional","affiliation":[{"name":"Avicenne Hospital AP-HP, Dermatology Department, , Bobigny ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Heidelberger","sequence":"additional","affiliation":[{"name":"Avicenne Hospital AP-HP, Dermatology Department, , Bobigny ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Picard","sequence":"additional","affiliation":[{"name":"University Hospital of Nice Dermatology Department, , Nice ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Troin","sequence":"additional","affiliation":[{"name":"University Hospital of Nice Dermatology Department, , Nice ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Gerard","sequence":"additional","affiliation":[{"name":"University Hospital of Bordeaux Dermatology Department, , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Kramkimel","sequence":"additional","affiliation":[{"name":"Cochin Hospital AP-HP, Dermatology Department, , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Steff-Naud","sequence":"additional","affiliation":[{"name":"CHI Aulnay-Sous-Bois Dermatology Department, , Aulnay-Sous-Bois ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Qu\u00e9reux","sequence":"additional","affiliation":[{"name":"University Hospital of Nantes Dermatology Department, , Nantes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gaudy-Marqueste","sequence":"additional","affiliation":[{"name":"H\u00f4pital Timone AP-HM, Dermatology and skin cancer Department, , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Lesage","sequence":"additional","affiliation":[{"name":"University Hospital of Montpellier Dermatology Department, , Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Mignard","sequence":"additional","affiliation":[{"name":"University Hospital of Rouen Dermatology Department, , Rouen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Jeudy","sequence":"additional","affiliation":[{"name":"University Hospital of Dijon Dermatology Department, , Dijon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jouary","sequence":"additional","affiliation":[{"name":"University Hospital of Pau Dermatology Department, , Pau ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Saint-Jean","sequence":"additional","affiliation":[{"name":"Institut de Canc\u00e9rologie de l\u2019Ouest Oncology Department, , Saint-Herblain ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barouyr","family":"Baroudjian","sequence":"additional","affiliation":[{"name":"Saint-Louis Hospital, Universit\u00e9 de Paris AP-HP, Oncodermatology Department, , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Archier","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Joseph AP-HM, Dermatology Department, , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[{"name":"Lille University Dermatology Department, , Lille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9leste","family":"Lebbe","sequence":"additional","affiliation":[{"name":"Saint-Louis Hospital, Universit\u00e9 de Paris AP-HP, Oncodermatology Department, , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Montaudi\u00e9","sequence":"additional","affiliation":[{"name":"University Hospital of Nice Dermatology Department, , Nice ,","place":["France"]},{"name":"INSERM U1065, Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 C\u00f4te d\u2019Azur , Nice ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"7","key":"2024100317281122200_CIT0001","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2020.02.021","article-title":"Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019","volume":"130","author":"Ugurel","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"2024100317281122200_CIT0002","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/EDBK_199047","article-title":"Melanoma","volume":"38","author":"Ascierto","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"2024100317281122200_CIT0003","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2024100317281122200_CIT0004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma [published correction appears in N Engl J Med. 2018 Nov 29;379(22):2185]","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2024100317281122200_CIT0005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024100317281122200_CIT0006","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3389\/fonc.2020.01290","article-title":"Mechanisms of cancer resistance to immunotherapy","volume":"10","author":"Bai","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"2024100317281122200_CIT0007","doi-asserted-by":"crossref","first-page":"e000398","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J ImmunoTher Cancer"},{"issue":"12","key":"2024100317281122200_CIT0008","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model","volume":"109","author":"Kimura","year":"2018","journal-title":"Cancer Sci"},{"issue":"2","key":"2024100317281122200_CIT0009","doi-asserted-by":"crossref","first-page":"e0212513","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD81 T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"2024100317281122200_CIT0010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000505695","article-title":"Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma","volume":"9","author":"Deng","year":"2020","journal-title":"Liver Cancer"},{"issue":"5","key":"2024100317281122200_CIT0011","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/hep.31921","article-title":"Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC","volume":"74","author":"Yi","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"2024100317281122200_CIT0012","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/0008-5472.CAN-20-2426","article-title":"Inhibition of FGFR reactivates IFNgamma signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies","volume":"82","author":"Adachi","year":"2022","journal-title":"Cancer Res"},{"issue":"7","key":"2024100317281122200_CIT0013","first-page":"e157247","article-title":"Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments antitumor activity in melanoma","volume":"8","author":"Tran","year":"2023","journal-title":"VJCI Insight"},{"issue":"1","key":"2024100317281122200_CIT0014","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.22.00221","article-title":"Phase II LEAP-004 study of lenvatinib plus pembrolizumab for melanoma with confirmed progression on a programmed cell death protein-1 or programmed death ligand 1 inhibitor given as monotherapy or in combination","volume":"41","author":"Arance","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"2024100317281122200_CIT0015","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2024100317281122200_CIT0016","doi-asserted-by":"crossref","first-page":"9026","DOI":"10.1200\/jco.2013.31.15_suppl.9026","article-title":"A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma","volume":"31","author":"O\u2019Day","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2024100317281122200_CIT0017","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"2024100317281122200_CIT0018","doi-asserted-by":"crossref","first-page":"1180988","DOI":"10.3389\/fonc.2023.1180988","article-title":"Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma","volume":"13","author":"Stoff","year":"2023","journal-title":"Front Oncol"},{"issue":"6","key":"2024100317281122200_CIT0019","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and immune evolution of melanoma acquiring MAPKi resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"issue":"21","key":"2024100317281122200_CIT0020","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-22-1528","article-title":"Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: a multicenter, open-label, single-arm phase II Study","volume":"28","author":"Mao","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"32","key":"2024100317281122200_CIT0021","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1200\/JCO.19.00210","article-title":"Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial","volume":"37","author":"Sheng","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024100317281122200_CIT0022","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int J Cancer"},{"issue":"1","key":"2024100317281122200_CIT0023","first-page":"638747","article-title":"Antitumor activity of lenvatinib (E7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models","volume":"2014","author":"Tohyama","year":"2014","journal-title":"J Thyroid Res"},{"issue":"16_suppl","key":"2024100317281122200_CIT0024","doi-asserted-by":"crossref","first-page":"9514","DOI":"10.1200\/JCO.2023.41.16_suppl.9514","article-title":"NeoPlus: a phase II study of neoadjuvant Lenvatinib and pembrolizumab in resectable mucosal melanoma.NeoPlus: a phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma","volume":"41","author":"Mao","year":"2023","journal-title":"J Clin Oncol"},{"issue":"26","key":"2024100317281122200_CIT0025","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"26","key":"2024100317281122200_CIT0026","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"2024100317281122200_CIT0027","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S1470-2045(21)00241-2","article-title":"Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111\/KEYNOTE-146): A phase 1b\/2 study","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024100317281122200_CIT0028","doi-asserted-by":"crossref","first-page":"107281","DOI":"10.1016\/j.intimp.2020.107281","article-title":"Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: a systematic review","volume":"91","author":"Mo","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"2024100317281122200_CIT0029","article-title":"Lenvatinib plus pembrolizumab (len + pembro) versus pembro alone for unresectable or metastatic melanoma (MEL): results of LEAP-003","author":"Arance","year":"2023"},{"issue":"23","key":"2024100317281122200_CIT0030","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/10\/e1364\/59558288\/oyae145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/10\/e1364\/59558288\/oyae145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T17:34:02Z","timestamp":1727976842000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/10\/e1364\/7704479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,7,2]]},"published-print":{"date-parts":[[2024,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae145","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,7,2]]}}}